Date: 04-Feb-2020

Lilly's REYVOW - a new class of acute treatment for Migraine (ditan), now available

INDIANAPOLIS, Jan. 31, 2020 /PRNewswire/ -- Eli Lilly and Company announced today that REYVOW™ (lasmiditan) C-V 50 mg and 100 mg tablets, an oral medication for the acute treatment of migraine with or without aura in adults, is now available for prescription and will be available in pharmacies in the next few days. REYVOW works differently than other acute treatments for migraine. REYVOW is a new class of acute treatment for migraine, as it is the first and only FDA-approved ditan, a 5-HT1F receptor agonist, believed to act both centrally and peripherally. REYVOW is available in 50 mg, 100 mg and 200 mg doses for patients, which offers dosing flexibility for physicians and other prescribers. Recent guidance issued by both the FDA and the American Headache Society raised the clinical bar by recommending migraine clinical trial efficacy demonstrates pain freedom and freedom from most bothersome symptoms, rather than just pain relief. REYVOW is the first FDA-approved acute medicine for migraine to meet this new standard. A migraine attack is often incapacitating and excruciating. In the International Burden of Migraine Study, a web-based survey of 9715 adults with migraine, 79% of patients reported experiencing severe pain during a migraine attack. Triptans are recommended as an acute therapy for migraine for appropriate patients by the American Headache Society. However, when speaking to patients with migraine, 79% said they would be willing to try another acute treatment.